Maximum Daily Dose of Gabapentin for Anxiety
The maximum daily dose of gabapentin for anxiety is 3600 mg/day, though this indication is off-label and evidence supporting its use for anxiety is limited. 1
FDA-Approved Dosing Context
The FDA has approved gabapentin for postherpetic neuralgia and epilepsy, not for anxiety disorders. According to the FDA label, the maximum daily dose is 3600 mg/day in divided doses for approved indications 1. For postherpetic neuralgia specifically, efficacy was demonstrated in the range of 1800-3600 mg/day, though additional benefit above 1800 mg/day was not clearly demonstrated in clinical trials 1.
Off-Label Use for Anxiety: Critical Limitations
Using gabapentin for anxiety is off-label and should be approached with significant caution. The evidence base is weak:
- A 2022 systematic review found only moderate evidence for gabapentinoids in anxiety states, with most positive data coming from preoperative anxiety studies rather than chronic anxiety disorders 2
- A small 2003 study in healthy volunteers showed anxiolytic effects at 800 mg (but not 400 mg) in simulated public speaking 3
- The 2026 restless legs syndrome guidelines note that patients with comorbid anxiety "may obtain additional benefit from gabapentinoids," but this is a secondary observation, not a primary indication 4
Practical Dosing Approach (If Prescribed Off-Label)
If gabapentin is being considered for anxiety despite limited evidence:
Starting dose:
- Begin at 300 mg/day (100 mg three times daily or 300 mg at bedtime) 1
- For patients >65 years: start at 100 mg/day 4
Titration:
- Increase by 100-300 mg every 1-7 days as tolerated 5
- Due to nonlinear absorption, doses >600 mg should be divided into multiple smaller doses throughout the day 4
Target dose range:
- Most patients respond to 900-1800 mg/day in divided doses 4
- Maximum: 3600 mg/day (1200 mg three times daily) 1
- Maximum time between doses should not exceed 12 hours 1
Critical Safety Considerations
Gabapentin carries significant risks that must be weighed against uncertain benefits for anxiety:
- Mood disturbance risk: Low but present risk of new-onset or worsening depression/suicidal ideation—requires careful monitoring, especially in patients with depression history 4
- Weight gain: 20% of patients experience clinically significant weight gain 4
- Abuse potential: Increased risk in patients with opioid use disorder history 4
- Falls risk: Particularly in elderly and those with gait disorders due to dizziness and unsteadiness 4
- Respiratory depression: Use with extreme caution with opioids or in respiratory failure 4
- Mortality concerns: A 2021 review noted 244 deaths involving pregabalin in 2019 in England, with rates exceeding diazepam 6
- Altered mental status: Higher doses (>600 mg/day) associated with increased hospitalization risk for confusion in older adults 7
Renal Dosing Adjustments
Mandatory dose reduction in renal impairment (renally excreted):
- CrCl ≥60: 900-3600 mg/day
- CrCl 30-59: 400-1400 mg/day
- CrCl 15-29: 200-700 mg/day
- CrCl <15: 100-300 mg/day
- Hemodialysis: supplemental post-dialysis dose required 1
Clinical Recommendation
Gabapentin should NOT be a first-line treatment for anxiety disorders. Evidence-based first-line treatments include SSRIs, SNRIs, and cognitive behavioral therapy. The 2021 review explicitly questions whether gabapentinoids should be prescribed long-term for anxiety given tolerance, dependence, and withdrawal issues similar to benzodiazepines 6. If used, it should be with strong justification, at the lowest effective dose, with close monitoring for adverse effects, and recognition that long-term efficacy and safety data are lacking 2, 6.